{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:24:42Z","timestamp":1794914682076,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["ZIAActf AI000416Projectf 41"],"award-info":[{"award-number":["ZIAActf AI000416Projectf 41"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000697","name":"Rhodes Scholarships","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000697","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000719","name":"Oxford University | St. John's College, University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000719","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Townsend-Jeantet Prize Charitable Trust"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The upsurge of mpox in Africa and the recent global outbreak have stimulated the development of new vaccines and therapeutics. We describe the construction of virus-like particle (VLP) vaccines in which modified M1, A35 and B6 proteins from monkeypox virus (MPXV) clade Ia are conjugated individually or together to a scaffold that accommodates up to 60 ligands using the SpyTag\/SpyCatcher nanoparticle system. Immunisation of female mice with VLPs induces higher anti-MPXV and anti-vaccinia virus (VACV) neutralizing antibodies than their soluble protein (SP) counterparts or modified VACV Ankara (MVA). Vaccination with individual single protein VLPs provides partial protection against lethal respiratory infections with VACV or MPXV clade IIa, whereas combinations or a chimeric VLP with all three antigens provide complete protection that is superior to SPs. Additionally, the VLP vaccine reduces the replication and spread of the virus at intranasal and intrarectal sites of inoculation. VLPs induce higher neutralizing activity than the Jynneos vaccine in rhesus macaques, and the VLP-induced antiserum provides better protection against MPXV and VACV than the Jynneos-induced antiserum when passively transferred to female mice. These data demonstrate that an mpox VLP vaccine derived from three MPXV clade Ia proteins protects against clade IIa MPXV and VACV, indicating cross-reactivity for orthopoxviruses.<\/jats:p>","DOI":"10.1038\/s41467-025-59826-8","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:13:25Z","timestamp":1747836805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates"],"prefix":"10.1038","volume":"16","author":[{"given":"Ahmed A.","family":"Belghith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxinne A.","family":"Ignacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory A.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8870-7147","authenticated-orcid":false,"given":"Mark R.","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3319-0314","authenticated-orcid":false,"given":"Debra S.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Brenchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-8564","authenticated-orcid":false,"given":"Bernard","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"59826_CR1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41564-024-01690-1","volume":"9","author":"B Moss","year":"2024","unstructured":"Moss, B. Understanding the biology of monkeypox virus to prevent future outbreaks. Nat. Microbiol. 9, 1408\u20131416 (2024).","journal-title":"Nat. Microbiol."},{"key":"59826_CR2","unstructured":"Satheshkumar, P. S. & Damon, I. in Fields Virology: DNA Viruses, Vol. 4 (eds Howley, P. M., Knipe, D. M., Cohen, J. L., & Damania, B. A.) Ch. 17, 614\u2013640 (Wolters Kluwer, 2021)."},{"key":"59826_CR3","doi-asserted-by":"publisher","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge, E. M. et al. The changing epidemiology of human monkeypox\u2014a potential threat? A systematic review. PLoS Negl. Trop. Dis. 16, e0010141 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"59826_CR4","unstructured":"Moss, B. & Smith, G. L. in Fields Virology, Vol. 2 (eds. Howley, P. M. & Knipe, D.M.) Ch. 16, 573\u2013613 (Wolters Kluwer, 2021)."},{"key":"59826_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000416456","volume":"17","author":"Z Jezek","year":"1988","unstructured":"Jezek, Z. & Fenner, F. Human monkeypox. Monogr. Virol. 17, 1\u2013140 (1988).","journal-title":"Monogr. Virol."},{"key":"59826_CR6","doi-asserted-by":"crossref","unstructured":"Doty, J. B. et al. Assessing monkeypox virus prevalence in small mammals at the human-animal interface in the Democratic Republic of the Congo. Viruses 9, 283 (2017).","DOI":"10.3390\/v9100283"},{"key":"59826_CR7","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1099\/vir.0.81215-0","volume":"86","author":"AM Likos","year":"2005","unstructured":"Likos, A. M. et al. A tale of two clades: monkeypox viruses. J. Gen. Virol. 86, 2661\u20132672 (2005).","journal-title":"J. Gen. Virol."},{"key":"59826_CR8","doi-asserted-by":"publisher","first-page":"e3001769","DOI":"10.1371\/journal.pbio.3001769","volume":"20","author":"C Happi","year":"2022","unstructured":"Happi, C. et al. Urgent need for a non-discriminatory and non-stigmatizing nomenclature for monkeypox virus. PLoS Biol. 20, e3001769 (2022).","journal-title":"PLoS Biol."},{"key":"59826_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/infdis\/jiac298","volume":"227","author":"D Forni","year":"2023","unstructured":"Forni, D., Molteni, C., Cagliani, R. & Sironi, M. Geographic structuring and divergence time frame of monkeypox virus in the endemic region. J. Infect. Dis. 227, 742\u2013751 (2023).","journal-title":"J. Infect. Dis."},{"key":"59826_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/oxfordjournals.bmb.a011720","volume":"54","author":"DL Heymann","year":"1998","unstructured":"Heymann, D. L., Szczeniowski, M. & Esteves, K. Re-emergence of monkeypox in Africa: a review of the past six years. Br. Med. Bull. 54, 693\u2013702 (1998).","journal-title":"Br. Med. Bull."},{"key":"59826_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3201\/eid2206.150579","volume":"22","author":"LD Nolen","year":"2016","unstructured":"Nolen, L. D. et al. Extended human-to-human transmission during a monkeypox outbreak in the Democratic Republic of the Congo. Emerg. Infect. Dis. 22, 1014\u20131021 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"59826_CR12","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/s41591-024-03130-3","volume":"30","author":"EH Vakaniaki","year":"2024","unstructured":"Vakaniaki, E. H. et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat. Med 30, 2791\u20132795 (2024).","journal-title":"Nat. Med"},{"key":"59826_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1473-3099(19)30294-4","volume":"19","author":"A Yinka-Ogunleye","year":"2019","unstructured":"Yinka-Ogunleye, A. et al. Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect. Dis. 19, 872\u2013879 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"59826_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1126\/science.add4153","volume":"378","author":"CM Gigante","year":"2022","unstructured":"Gigante, C. M. et al. Multiple lineages of monkeypox virus detected in the United States, 2021-2022. Science 378, 560\u2013564 (2022).","journal-title":"Science"},{"key":"59826_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","volume":"239","author":"B Moss","year":"2011","unstructured":"Moss, B. Smallpox vaccines: targets of protective immunity. Immunol. Rev. 239, 8\u201326 (2011).","journal-title":"Immunol. Rev."},{"key":"59826_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm7122e1","volume":"71","author":"AK Rao","year":"2022","unstructured":"Rao, A. K. et al. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the Advisory Committee on Immunization Practices-United States, 2022. Mmwr-Morbidity Mortal. Wkly. Rep. 71, 734\u2013742 (2022).","journal-title":"Mmwr-Morbidity Mortal. Wkly. Rep."},{"key":"59826_CR17","doi-asserted-by":"crossref","unstructured":"Deputy, N. P. et al. Vaccine effectiveness of JYNNEOS against Mpox disease in the United States. New Engl. J. Med. 388, 2434\u20132443 (2023).","DOI":"10.1056\/NEJMoa2215201"},{"key":"59826_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","volume":"72","author":"AF Dalton","year":"2023","unstructured":"Dalton, A. F. et al. Estimated effectiveness of JYNNEOS vaccine in preventing Mpox: a multijurisdictional case-control study\u2014United States, August 19, 2022\u2013March 31, 2023. MMWR Morb. Mortal. Wkly Rep. 72, 553\u2013558 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"59826_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.15585\/mmwr.mm7220a4","volume":"72","author":"ES Rosenberg","year":"2023","unstructured":"Rosenberg, E. S. et al. Effectiveness of JYNNEOS vaccine against diagnosed Mpox infection\u2014New York, 2022. MMWR Morb. Mortal. Wkly Rep. 72, 559\u2013563 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"59826_CR20","doi-asserted-by":"crossref","unstructured":"Zaeck, L. M. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat. Med. 29, 270\u2013278 (2023).","DOI":"10.1038\/s41591-022-02090-w"},{"key":"59826_CR21","doi-asserted-by":"crossref","unstructured":"Collier, A.Y. et al. Decline of Mpox Antibody Responses After Modified Vaccinia Ankara-Bavarian Nordic Vaccination. JAMA 332, 1669\u20131672 (2024).","DOI":"10.1001\/jama.2024.20951"},{"key":"59826_CR22","doi-asserted-by":"publisher","unstructured":"Leeuwen, L. et al. Orthopoxvirus-specific antibodies wane to undetectable levels 1 year after MVA-BN vaccination of at-risk individuals, the Netherlands, 2022 to 2023. Eurosurveillance 29, 8\u201312. https:\/\/doi.org\/10.2807\/1560-7917.Es.2024.29.38.2400575 (2024).","DOI":"10.2807\/1560-7917.Es.2024.29.38.2400575"},{"key":"59826_CR23","doi-asserted-by":"publisher","unstructured":"Oom, A. L. et al. The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00253-25 (2025).","DOI":"10.1128\/jvi.00253-25"},{"key":"59826_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3540","volume":"15","author":"AW Freyn","year":"2023","unstructured":"Freyn, A. W. et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med. 15, eadg3540 (2023).","journal-title":"Sci. Transl. Med."},{"key":"59826_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41628-5","volume":"14","author":"F Hou","year":"2023","unstructured":"Hou, F. et al. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge. Nat. Commun. 14, 5925 (2023).","journal-title":"Nat. Commun."},{"key":"59826_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41422-023-00792-5","volume":"33","author":"Z Fang","year":"2023","unstructured":"Fang, Z. et al. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res. 33, 407\u2013410 (2023).","journal-title":"Cell Res."},{"key":"59826_CR27","doi-asserted-by":"publisher","unstructured":"Sang, Y. et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Signal Transduct. Target. Therapy. https:\/\/doi.org\/10.1038\/s41392-023-01432-5 (2023).","DOI":"10.1038\/s41392-023-01432-5"},{"key":"59826_CR28","doi-asserted-by":"crossref","unstructured":"Yang, X. D. et al. Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice. J. Med. Virol. 95, e29140 (2023).","DOI":"10.1002\/jmv.29140"},{"key":"59826_CR29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.cell.2024.01.017","volume":"187","author":"A Zuiani","year":"2024","unstructured":"Zuiani, A. et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell 187, 1363\u20131373.e1312 (2024).","journal-title":"Cell"},{"key":"59826_CR30","doi-asserted-by":"crossref","unstructured":"Mucker, E. M. et al. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell 187, 5540\u20135553.e10 (2024).","DOI":"10.1016\/j.cell.2024.08.043"},{"key":"59826_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/298347a0","volume":"298","author":"P Valenzuela","year":"1982","unstructured":"Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G. & Hall, B. D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298, 347\u2013350 (1982).","journal-title":"Nature"},{"key":"59826_CR32","doi-asserted-by":"publisher","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","volume":"89","author":"R Kirnbauer","year":"1992","unstructured":"Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R. & Schiller, J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89, 12180\u201312184 (1992).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59826_CR33","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1128\/jvi.71.10.7207-7213.1997","volume":"71","author":"TC Li","year":"1997","unstructured":"Li, T. C. et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J. Virol. 71, 7207\u20137213 (1997).","journal-title":"J. Virol."},{"key":"59826_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00330-7","volume":"6","author":"B Nguyen","year":"2021","unstructured":"Nguyen, B. & Tolia, N. H. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6, 70 (2021).","journal-title":"NPJ Vaccines"},{"key":"59826_CR35","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.copbio.2021.09.012","volume":"73","author":"RA Hills","year":"2022","unstructured":"Hills, R. A. & Howarth, M. Virus-like particles against infectious disease and cancer: guidance for the nano-architect. Curr. Opin. Biotechnol. 73, 346\u2013354 (2022).","journal-title":"Curr. Opin. Biotechnol."},{"key":"59826_CR36","doi-asserted-by":"publisher","first-page":"E690","DOI":"10.1073\/pnas.1115485109","volume":"109","author":"B Zakeri","year":"2012","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. USA 109, E690\u2013E697 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59826_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-016-0181-1","volume":"14","author":"S Thrane","year":"2016","unstructured":"Thrane, S. et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J. Nanobiotechnol. 14, 30 (2016).","journal-title":"J. Nanobiotechnol."},{"key":"59826_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep19234","volume":"6","author":"KD Brune","year":"2016","unstructured":"Brune, K. D. et al. Plug-and-display: decoration of virus-Like particles via isopeptide bonds for modular immunization. Sci. Rep. 6, 19234 (2016).","journal-title":"Sci. Rep."},{"key":"59826_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1574-1","volume":"15","author":"CM Janitzek","year":"2016","unstructured":"Janitzek, C. M. et al. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. Malar. J. 15, 545 (2016).","journal-title":"Malar. J."},{"key":"59826_CR40","doi-asserted-by":"publisher","first-page":"e0247963","DOI":"10.1371\/journal.pone.0247963","volume":"16","author":"AA Cohen","year":"2021","unstructured":"Cohen, A. A. et al. Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers. PLoS One 16, e0247963 (2021).","journal-title":"PLoS One"},{"key":"59826_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1216364","volume":"13","author":"V Lampinen","year":"2023","unstructured":"Lampinen, V. et al. SpyTag\/SpyCatcher display of influenza M2e peptide on norovirus-like particle provides stronger immunization than direct genetic fusion. Front Cell Infect. Microbiol. 13, 1216364 (2023).","journal-title":"Front Cell Infect. Microbiol."},{"key":"59826_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.virol.2021.12.001","volume":"566","author":"S Heinimaki","year":"2022","unstructured":"Heinimaki, S. et al. Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag\/SpyCatcher technology. Virology 566, 89\u201397 (2022).","journal-title":"Virology"},{"key":"59826_CR43","doi-asserted-by":"crossref","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","DOI":"10.1056\/NEJMoa2026920"},{"key":"59826_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20654-7","volume":"12","author":"TK Tan","year":"2021","unstructured":"Tan, T. K. et al. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. Nat. Commun. 12, 542 (2021).","journal-title":"Nat. Commun."},{"key":"59826_CR45","doi-asserted-by":"publisher","first-page":"e1009897","DOI":"10.1371\/journal.ppat.1009897","volume":"17","author":"Q Geng","year":"2021","unstructured":"Geng, Q. et al. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLoS Pathog. 17, e1009897 (2021).","journal-title":"PLoS Pathog."},{"key":"59826_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74949-2","volume":"10","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci. Rep. 10, 18149 (2020).","journal-title":"Sci. Rep."},{"key":"59826_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0839","volume":"377","author":"AA Cohen","year":"2022","unstructured":"Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).","journal-title":"Science"},{"key":"59826_CR48","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","volume":"78","author":"C Fogg","year":"2004","unstructured":"Fogg, C. et al. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J. Virol. 78, 10230\u201310237 (2004).","journal-title":"J. Virol."},{"key":"59826_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ange.202009663","volume":"133","author":"R Rahikainen","year":"2021","unstructured":"Rahikainen, R. et al. Overcoming symmetry mismatch in vaccine nanoassembly through spontaneous amidation. Angew. Chem. Weinh. Bergstr. Ger. 133, 325\u2013334 (2021).","journal-title":"Angew. Chem. Weinh. Bergstr. Ger."},{"key":"59826_CR50","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1099\/0022-1317-71-11-2761","volume":"71","author":"JD Williamson","year":"1990","unstructured":"Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J. Gen. Virol. 71, 2761\u20132767 (1990).","journal-title":"J. Gen. Virol."},{"key":"59826_CR51","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/infdis\/jiab111","volume":"224","author":"SE Frey","year":"2021","unstructured":"Frey, S. E. et al. Human antibody responses following vaccinia immunization using protein microarrays and correlation with cell-mediated immunity and antibody-dependent cellular cytotoxicity responses. J. Infect. Dis. 224, 1372\u20131382 (2021).","journal-title":"J. Infect. Dis."},{"key":"59826_CR52","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.1128\/JVI.77.19.10684-10688.2003","volume":"77","author":"PL Earl","year":"2003","unstructured":"Earl, P. L., Americo, J. L. & Moss, B. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J. Virol. 77, 10684\u201310688 (2003).","journal-title":"J. Virol."},{"key":"59826_CR53","doi-asserted-by":"publisher","first-page":"8172","DOI":"10.1128\/JVI.00621-10","volume":"84","author":"JL Americo","year":"2010","unstructured":"Americo, J. L., Moss, B. & Earl, P. L. Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J. Virol. 84, 8172\u20138180 (2010).","journal-title":"J. Virol."},{"key":"59826_CR54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220415120","volume":"120","author":"JL Americo","year":"2023","unstructured":"Americo, J. L., Earl, P. L. & Moss, B. Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model. Proc. Natl. Acad. Sci. USA 120, e2220415120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59826_CR55","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.virol.2013.11.017","volume":"449","author":"JL Americo","year":"2014","unstructured":"Americo, J. L. et al. Susceptibility of the wild-derived inbred CAST\/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging. Virology 449, 120\u2013132 (2014).","journal-title":"Virology"},{"key":"59826_CR56","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.virol.2014.11.015","volume":"475","author":"PL Earl","year":"2015","unstructured":"Earl, P. L., Americo, J. L., Cotter, C. A. & Moss, B. Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni). Virology 475, 150\u2013158 (2015).","journal-title":"Virology"},{"key":"59826_CR57","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/bit.20059","volume":"86","author":"JM Ignowski","year":"2004","unstructured":"Ignowski, J. M. & Schaffer, D. V. Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol. Bioeng. 86, 827\u2013834 (2004).","journal-title":"Biotechnol. Bioeng."},{"key":"59826_CR58","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.antiviral.2008.01.158","volume":"78","author":"KE Luker","year":"2008","unstructured":"Luker, K. E. & Luker, G. D. Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antivir. Res 78, 179\u2013187 (2008).","journal-title":"Antivir. Res"},{"key":"59826_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3201\/eid3001.231164","volume":"30","author":"EM Kibungu","year":"2024","unstructured":"Kibungu, E. M. et al. Clade I-associated Mpox cases associated with sexual contact, the Democratic Republic of the Congo. Emerg. Infect. Dis. 30, 172\u2013176 (2024).","journal-title":"Emerg. Infect. Dis."},{"key":"59826_CR60","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","volume":"24","author":"J Kenner","year":"2006","unstructured":"Kenner, J., Cameron, F., Empig, C., Jobes, D. V. & Gurwith, M. LC16m8: an attenuated smallpox vaccine. Vaccine 24, 7009\u20137022 (2006).","journal-title":"Vaccine"},{"key":"59826_CR61","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1080\/14760584.2024.2397006","volume":"23","author":"JD Grabenstein","year":"2024","unstructured":"Grabenstein, J. D. & Hacker, A. Vaccines against mpox: MVA-BN and LC16m8. Expert Rev. Vaccines 23, 796\u2013811 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"59826_CR62","first-page":"295","volume":"62","author":"EA Boulter","year":"1969","unstructured":"Boulter, E. A. Protection against poxviruses. Proc. R. Soc. Med. 62, 295\u2013297 (1969).","journal-title":"Proc. R. Soc. Med."},{"key":"59826_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1099\/0022-1317-13-1-19","volume":"13","author":"GS Turner","year":"1971","unstructured":"Turner, G. S. & Squires, E. J. Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. J. Gen. Virol. 13, 19\u201325 (1971).","journal-title":"J. Gen. Virol."},{"key":"59826_CR64","doi-asserted-by":"publisher","first-page":"e1008505","DOI":"10.1371\/journal.ppat.1008505","volume":"16","author":"PL Earl","year":"2020","unstructured":"Earl, P. L., Americo, J. L. & Moss, B. Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses. PLoS Pathog. 16, e1008505 (2020).","journal-title":"PLoS Pathog."},{"key":"59826_CR65","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa2207323","volume":"387","author":"JP Thornhill","year":"2022","unstructured":"Thornhill, J. P. et al. Monkeypox virus infection in humans across 16 countries-April\u2013June 2022. N. Engl. J. Med. 387, 679\u2013691 (2022).","journal-title":"N. Engl. J. Med."},{"key":"59826_CR66","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs 9, 767\u2013773 (2017).","journal-title":"MAbs"},{"key":"59826_CR67","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/807564","volume":"2014","author":"VA Graham","year":"2014","unstructured":"Graham, V. A. et al. Efficacy of primate humoral passive transfer in a murine model of pneumonic plague is mouse strain-dependent. J. Immunol. Res. 2014, 807564 (2014).","journal-title":"J. Immunol. Res."},{"key":"59826_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.21","volume":"1","author":"K Muthumani","year":"2016","unstructured":"Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines 1, 16021 (2016).","journal-title":"NPJ Vaccines"},{"key":"59826_CR69","doi-asserted-by":"publisher","first-page":"e23791","DOI":"10.1371\/journal.pone.0023791","volume":"6","author":"MK Howard","year":"2011","unstructured":"Howard, M. K. et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 6, e23791 (2011).","journal-title":"PLoS One"},{"key":"59826_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11122-x","volume":"12","author":"AM Ortiz","year":"2022","unstructured":"Ortiz, A. M. et al. Butyrate administration is not sufficient to improve immune reconstitution in antiretroviral-treated SIV-infected macaques. Sci. Rep. 12, 7491 (2022).","journal-title":"Sci. Rep."},{"key":"59826_CR71","doi-asserted-by":"publisher","first-page":"8613","DOI":"10.1128\/JVI.00606-07","volume":"81","author":"AC Townsley","year":"2007","unstructured":"Townsley, A. C. & Moss, B. Two distinct low-pH steps promote entry of vaccinia virus. J. Virol. 81, 8613\u20138620 (2007).","journal-title":"J. Virol."},{"key":"59826_CR72","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1073\/pnas.0401165101","volume":"101","author":"LS Wyatt","year":"2004","unstructured":"Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101, 4590\u20134595 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"59826_CR73","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1128\/jvi.66.7.4170-4179.1992","volume":"66","author":"R Blasco","year":"1992","unstructured":"Blasco, R. & Moss, B. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J. Virol. 66, 4170\u20134179 (1992).","journal-title":"J. Virol."},{"key":"59826_CR74","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","volume":"79","author":"S Lustig","year":"2005","unstructured":"Lustig, S. et al. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79, 13454\u201313462 (2005).","journal-title":"J. Virol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59826-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T15:03:39Z","timestamp":1747839819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59826-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59826"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59826-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H. is an inventor on a patent regarding spontaneous amide bond formation (EP2534484), a SpyBiotech founder, and an inventor on a patent application regarding SpyTag003:SpyCatcher003. A.A.B. and B.M. are inventors on a U.S. government patent application for nanoparticle mpox vaccines. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4726"}}